Bio-Path Holdings (NASDAQ:BPTH)’s share price was down 7% on Thursday . The company traded as low as $2.00 and last traded at $2.14. Approximately 431,654 shares changed hands during mid-day trading, an increase of 45% from the average daily volume of 297,826 shares. The stock had previously closed at $2.00.
Separately, ValuEngine upgraded shares of Bio-Path from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The stock has a market capitalization of $22.68, a P/E ratio of -2.52 and a beta of 2.73.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.